Plain-English translation of NCT03384745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested a new medication called Sonelokimab (M1095) to treat moderate to severe psoriasis—a chronic skin condition that causes thick, scaly patches. Researchers studied the medication in nearly 300 people across North America and Europe to find out which dose worked best and how safe it was. The trial compared this treatment to both a placebo and an existing psoriasis medication to see how effective it truly was.
While treatments for psoriasis exist today, many patients do not get complete relief from their symptoms. Researchers wanted to test whether this new medication could work better for people with moderate to severe disease and help improve their quality of life.
Participants received injections of either the new medication, a placebo, or an existing psoriasis drug at scheduled visits over 12 weeks, with some doses given every 4 or 8 weeks. The study then continued for an additional 40 weeks of follow-up to monitor how well the treatment worked and how safe it was. Participants had blood tests, skin evaluations, and regular clinic visits to track how their psoriasis responded to treatment.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States